Detalhe da pesquisa
1.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Cell
; 186(16): 3476-3498.e35, 2023 08 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37541199
2.
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer.
Cell
; 187(4): 1016, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38364782
3.
Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
Br J Cancer
; 130(5): 861-868, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38195887
4.
Cancer case trends following the onset of the COVID-19 pandemic: A community-based observational study with extended follow-up.
Cancer
; 128(7): 1475-1482, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34919267
5.
Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
Int J Gynecol Cancer
; 29(2): 325-333, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30700568
6.
Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.
J Virol
; 91(6)2017 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28077642
7.
Targeted single molecule mutation detection with massively parallel sequencing.
Nucleic Acids Res
; 44(3): e22, 2016 Feb 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-26384417
8.
The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
Cancer
; 122(22): 3509-3518, 2016 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27447168
9.
Identification of novel candidate plasma metabolite biomarkers for distinguishing serous ovarian carcinoma and benign serous ovarian tumors.
Gynecol Oncol
; 140(1): 138-44, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-26521694
10.
Identifying post-menopausal women at elevated risk for epithelial ovarian cancer.
Gynecol Oncol
; 139(2): 253-60, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26343159
11.
ESRRA-C11orf20 is a recurrent gene fusion in serous ovarian carcinoma.
PLoS Biol
; 9(9): e1001156, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21949640
12.
Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations.
Gynecol Oncol
; 132(2): 280-6, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24333842
13.
High-throughput sequencing of T-cell receptors reveals a homogeneous repertoire of tumour-infiltrating lymphocytes in ovarian cancer.
J Pathol
; 231(4): 433-440, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24027095
14.
An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.
Nucleic Acids Res
; 40(2): 499-510, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21917857
15.
Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study.
JCO Precis Oncol
; 7: e2200609, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37027810
16.
Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling.
Gynecol Oncol
; 126(2): 229-35, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22564716
17.
Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125.
Gynecol Oncol
; 125(1): 65-9, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22155417
18.
Involvement in decision-making about treatment and ovarian cancer survivor quality of life.
Gynecol Oncol
; 124(3): 465-70, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-22044688
19.
A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.
Gynecol Oncol
; 127(3): 538-43, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22922531
20.
Translational development of a tumor junction opening technology.
Sci Rep
; 12(1): 7753, 2022 05 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35562182